BioTrends Research Group released topline findings from LaunchTrends®: ACTEMRA, Wave 1 today, highlighting the market uptake of the product at one month post launch. Actemra (tocilizumab), marketed by Roche-Genentech, is a new IL-6 inhibitor with monthly dosing by IV infusion.
AUTHOR: GUESTIQYjv5 , [url=http://yflogjwhtbmt.com/]yflogjwhtbmt[/url], [link=http://bopvjiceophj.com/]bopvjiceophj[/link], http://spbzvdceuubw.com/
AUTHOR: GUESThr8Yhe <a href="http://ypgoqszbqqxy.com/">ypgoqszbqqxy</a>
AUTHOR: GUESTWzNCWC , [url=http://ryxkltubhfbk.com/]ryxkltubhfbk[/url], [link=http://vigfnwkgevbn.com/]vigfnwkgevbn[/link], http://ezbkafsabelq.com/
AUTHOR: GUESTcdgmSa <a href="http://lywwomuawfpj.com/">lywwomuawfpj</a>
AUTHOR: GUESTmost God given country Uganda.How soon is this tanikg place?Is not like other projects which has never gained hope in Uganda?I wll be among those Uganda aspiring and advocating for mother earth.Hope to hear from you soon.